Trial site

Instituto Mederi de Pesquisa e Saude

Passo Fundo, 99010-120, BrazilNot linked to an institution yet

17running trials
6closed trials

The trials here

What the 24 trials at this site are about, from their registry records.

Conditions: Type 2 diabetes4 trials
Crohn's disease3 trials
Depression3 trials
Heart failure3 trials
Alzheimer disease2 trials
Coronary artery disease2 trials
Insomnia2 trials
Obesity2 trials
Stroke2 trials
Asthma1 trial
Atrial fibrillation1 trial
Chronic kidney disease1 trial
and 10 more
Phase: Phase 318 trials
Phase 2/33 trials
Phase 22 trials
Phase 41 trial
Status: Active, not recruiting9 trials
Completed5 trials
Recruiting5 trials
Not yet recruiting2 trials
Enrolling by invitation1 trial
Suspended1 trial
Terminated1 trial
Lead sponsor: Janssen Research & Development, LLC8 trials
Eli Lilly and Company6 trials
ACADIA Pharmaceuticals Inc.2 trials
Boehringer Ingelheim2 trials
Guerbet1 trial
and 5 more

Running trials

Recruiting
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
NCT07775300· Phase 3· Eli Lilly and Company· Source
Contact: Jacson Hubner (principal investigator)
Recruiting
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
NCT07668336· Phase 3· Eli Lilly and Company· Source
Contact: Hugo Kurtz Lisboa (principal investigator)
Recruiting
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
NCT07219173· Phase 2· Eli Lilly and Company· Source
Contact: Tiago Simon (principal investigator)
Recruiting
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Active, not recruiting
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390· Phase 3· Eli Lilly and Company· Source
Enrolling by invitation
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
NCT06194799· Phase 3· ACADIA Pharmaceuticals Inc.· Source
Active, not recruiting
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
NCT06408935· Phase 3· Janssen-Cilag Ltd.· Source
Recruiting
ACP-204 in Adults With Alzheimer's Disease Psychosis
NCT06159673· Phase 2/3· ACADIA Pharmaceuticals Inc.· Source
Contact: Christine Murphy
Active, not recruiting
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus
NCT05648500· Phase 3· Viatris Innovation GmbH· Source
Active, not recruiting
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease
NCT05197049· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
NCT04373564· Phase 4· Guerbet· Source
Contact: Keyla Deucher
Active, not recruiting
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
NCT04548999· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT04033445· Phase 2/3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
NCT03466411· Phase 2/3· Janssen Research & Development, LLC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Alzheimer disease2 recruiting
Heart failure2 recruiting
Asthma1 recruiting
Colorectal cancer1 recruiting
Depression1 recruiting
Liver and biliary tract cancer1 recruiting
Pancreatic cancer1 recruiting
Prostate cancer1 recruiting
Type 2 diabetes1 recruiting

Closed trials

Terminated
Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
NCT06097260· Phase 2· Pliant Therapeutics, Inc.· Source
Completed
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
NCT05872620· Phase 3· Eli Lilly and Company· Source
Completed
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
NCT05754957· Phase 3· Janssen Research & Development, LLC· Source
Completed
A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both
NCT05260021· Phase 3· Eli Lilly and Company· Source
Completed
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant
NCT04533529· Phase 3· Janssen Research & Development, LLC· Source
Completed
Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer
NCT04205812· Phase 3· Incyte Corporation· Source

Site data: ClinicalTrials.govUpdated 13 Nov 2026

Report an error